New clinical trial to investigate affects of CBD on Parkinson’s related psychosis

A pioneering clinical trial is set to investigate the use of cannabidiol (CBD) in people with Parkinson’s-related psychosis. Parkinson’s UK will be partnering with scientists at King’s College London in the first large-scale trial which aims to provide preliminary evidence for the safety and efficacy of CBD to alleviate the symptoms of Parkinson’s-related psychosis, characterised by hallucinations and delusions.

Continue Reading